VICTORIA, BRITISH COLUMBIA--(Marketwire - Nov. 26, 2007) - CardioComm Solutions Inc. (TSX VENTURE:CCG) (new symbol effective November 26, 2007: EKG) ("CardioComm" or the "Company") announces that the TSX Venture Exchange has given final approval to the one-for-five (1:5) consolidation of the Company's common shares pursuant to a special resolution of the Company's shareholders passed on November 15, 2007 at the Company's special general meeting of shareholders.

Effective at the opening of the TSX Venture Exchange on November 26, 2007, the common shares of the Company will commence trading on the Exchange on a consolidated basis under the symbol "EKG" and under CUSIP number 14159N2086. As part of the consolidation, the name of the Company will change to "CardioComm Solutions, Inc."

Letters of transmittal were mailed to the shareholders of the Company along with the materials for the Company's special general meeting of shareholders. The Company's shareholders are requested to send their certificates representing pre-consolidation shares to Computershare Trust Services Inc. at its offices in Toronto to be exchanged for certificates representing the appropriate number of post-consolidation shares.

Brad Harlow, Chairman of the Board said, "this marks the beginning of a new era for CardioComm. We have the financial position and the support to move forward quickly with the launch of our new GlobalCardio 12 Lead System and we are well positioned to make advances in many areas moving into 2008."

Dr. Anatoly Langer, Chair of the Canadian Heart Research Centre and a member of the board, added, "we are very pleased with this new beginning which marks an exciting change in the direction of the Company re-focusing our energy on GlobalCardio enabling web access and inexpensive delivery of the 12 lead EKG, the most commonly performed test in the work up of a patient with heart disease by physicians around the world."

About CardioComm Solutions Inc.

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions Inc.

Brad Harlow, Chairman of the Board

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.